Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

This study has been completed.
Information provided by (Responsible Party):
Purdue Pharma LP Identifier:
First received: August 30, 2010
Last updated: August 27, 2014
Last verified: August 2014

The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy.

Condition Intervention Phase
Drug: Oxycodone HCl controlled-release tablets
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics

Resource links provided by NLM:

Further study details as provided by Purdue Pharma LP:

Primary Outcome Measures:
  • The number of participants with adverse events as a measure of safety. [ Time Frame: Up to 4 weeks (during the study) and 7-10 days poststudy (safety follow-up assessment). ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To characterize the efficacy and provide additional pharmacokinetics (PK) data of oxycodone hydrochloride controlled-release tablets [ Time Frame: 2-4 and 4-6 hours (hrs) after the first dose on Day 1 and immediately pre-dose and 2-4 hrs after dose at Visit 2 and/or Visit 3. ] [ Designated as safety issue: No ]
    To characterize the efficacy and provide additional pharmacokinetics (PK) data for a population PK model of oxycodone hydrochloride controlled-release tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy.

Enrollment: 155
Study Start Date: November 2010
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oxycodone HCl controlled-release
Oxycodone hydrochloride (HCl) controlled-release (CR)
Drug: Oxycodone HCl controlled-release tablets
Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
Other Name: OxyContin


Ages Eligible for Study:   6 Years to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria include:

  • Male and female patients aged 6 to 16 years, inclusive, who are expected to require ongoing around-the-clock opioid treatment equivalent to at least 20-mg daily dose of oxycodone for at least 2 weeks for management of moderate to severe (based on the investigator's judgment) malignant or nonmalignant pain.
  • Patients must be opioid tolerant, ie, have been treated with opioids for at least the 5 consecutive days prior to dosing and with at least 20 mg daily of oxycodone or the equivalent during at least the last 48 hours prior to the start of study drug dosing and have tolerated the therapy, as demonstrated at the start of study drug dosing.
  • Patients who are currently using transdermal fentanyl should have been on the patch for at least 3 days before removing the patch and oxycodone hydrochloride (HCl) controlled-release (CR) treatment can only be initiated at least 18 hours following the removal of the transdermal fentanyl patch.
  • Patients must not require more than a 240-mg total daily dose of oxycodone HCl CR tablets.
  • Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.
  • Patients must not be currently on an investigational medication/therapy at the start of screening or during the study.

Exclusion Criteria include:

  • Female patients who are pregnant or lactating.
  • Patients who are allergic to oxycodone or have a history of allergies to other opioids (this criterion does not include patients who have experienced common opioid side effects [eg, nausea, constipation]).
  • Patients who have received epidural opioids < 2 hours prior to the first dose of study drug or who have received epidural morphine < 12 hours prior to the first dose of study drug.
  • Patients who are contraindicated for the use of opioids.
  • Patients who are contraindicated for blood sampling.
  • Patients who are currently being maintained on methadone for pain.
  • Patients who have any planned surgery during the course of the study, with the exception of the placement of central or peripheral venous access devices.
  • Patients who have had surgery within 5 days prior to Day 1 (day of first dose of study drug).
  • Patients who, in the investigator's opinion, have an underlying gastrointestinal condition or other disorder that may predispose them to obstruction.

Other protocol-specific inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01192295

  Hide Study Locations
United States, Alabama
Children's Hospital of Alabama
Birmingham, Alabama, United States, 35233
University of South Alabama, Children's and Women's Hospital
Mobile, Alabama, United States, 36604
United States, Arizona
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Children's Hospital of Orange County
Orange, California, United States, 92868
LS Packard Children's Hospital
Palo Alto, California, United States, 94304
Bayview Research Group, LLC
Paramount, California, United States, 90723
Shriners Hospitals for Children Northern California
Sacramento, California, United States, 95817
United States, Colorado
The Children's Hospital
Aurora, Colorado, United States, 80045
United States, Connecticut
Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106
United States, Delaware
Alfred I. duPont Hospital for Children
Wilmington, Delaware, United States, 19803
United States, Florida
Sanitas Research
Coral Gables, Florida, United States, 33134
Memorial Regional Hospital
Hollywood, Florida, United States, 33021
Jackson Memorial Hospital/University of Miami
Miami, Florida, United States, 33136
Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, Michigan
Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States, 49503
United States, Missouri
Children's Blood Disorders & Cancer Unit
Columbia, Missouri, United States, 65201
St. John's Mercy Medical Center
St. Louis, Missouri, United States, 63141
United States, New York
New York University Langone Medical Center
New York, New York, United States, 10016
Stony Brook University Hospital
Stony Brook, New York, United States, 11794
United States, North Carolina
Presbyterian Blume Pediatric Hematology and Oncology Clinic
Charlotte, North Carolina, United States, 28204
Duke University Medical Center
Durham, North Carolina, United States, 22710
United States, Ohio
Akron Children's Hospital
Akron, Ohio, United States, 44308
United States, Oklahoma
Department of Pediatrics, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
The Children's Hospital at OUMC
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Legacy Emanuel Children's Hospital
Portland, Oregon, United States, 97227
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Tennessee
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, United States, 37232
United States, Texas
Children's Medical Ctr of Dallas
Dallas, Texas, United States, 75235
Research Facility
The Woodlands, Texas, United States, 77381
United States, Utah
Primary Children's Medical Center
Salt Lake City, Utah, United States, 84113
United States, Virginia
Children's Hospital of the King's Daughters
Norfolk, Virginia, United States, 23507
Pediatric Hematology and Oncology, Virginia Commonwealth University Health System
Richmond, Virginia, United States, 23298
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Agia Sophia Children's Hospital
Athens, Greece, 115 27
Aglaia Kyriakou - Elpida Children's Oncology Unit
Athens, Greece, 115 27
Semmelweis Egyetem, II. sz. Gyermekgyogyaszati Klinika
Budapest, Hungary, H-1094
Soroka University Medical Center
Beer Sheva, Israel, 84101
Mayer Children Hospital, Rambam Medical Center
Haifa, Israel, 31096
Hadassah Medical Organization, Ein Kerem
Jerusalem, Israel, 91120
Schneider Children Medical Center of Israel
Petach Tikva, Israel, 49202
Sheba Medical Center
Tel HaShomer, Israel, 52621
New Zealand
Starship Children's Health
Grafton, Auckland, New Zealand, 1023
Spitalul Clinic Judetean de Urgenta Targu Mures, Clinica pediatrie I
Targu Mures, Romania, 540136
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08025
United Kingdom
Sheffield Children's Hospital
Sheffield, United Kingdom, S10 2TH
Sponsors and Collaborators
Purdue Pharma LP
  More Information

Additional Information:
No publications provided

Responsible Party: Purdue Pharma LP Identifier: NCT01192295     History of Changes
Other Study ID Numbers: OTR3001, 2010-020471-23
Study First Received: August 30, 2010
Last Updated: August 27, 2014
Health Authority: United States: Food and Drug Administration
Estonia: The State Agency of Medicine
Finland: Finnish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Israel: Ministry of Health
New Zealand: Medsafe
Greece: National Organization of Medicines
Hungary: National Institute of Pharmacy
Poland: Ministry of Health
Belgium: Federal Agency for Medicinal Products and Health Products
Romania: Ministry of Public Health
Guatemala: Ministry of Public Health and Social Assistance
Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Purdue Pharma LP:
Malignant pain
Nonmalignant pain
Moderate to severe malignant or nonmalignant pain

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 27, 2014